Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Racial and Ethnic Differences in Outcomes of HCC

Clin Gastroenterol Hepatol; ePub 2018 May 31; Rich, et al

Racial/ethnic differences in outcomes of hepatocellular carcinoma (HCC) was associated with differences in detection of tumors at early stages and receipt of curative treatment among patients diagnosed with HCC, a recent study found. Researchers performed a retrospective study of patients with HCC from January 2008 through July 2017 at 2 large US health centers. They aimed to characterize racial and ethnic differences in HCC presentation, treatment, and survival. They found:

  • Among the 1,117 patients with HCC (35.9% white, 34.3% black, 29.7% Hispanic), 463 (41.5%) were diagnosed with early-stage HCC and 322 underwent curative treatment.
  • Hispanic and black patients were less likely to be diagnosed with early-stage HCC than white patients.
  • Among those with early-stage HCC, both Hispanic and black patients were likely to undergo curative treatment vs whites.
  • Black and Hispanic patients had shorter median survival times vs white patients.
  • After adjustment, black patients had significantly higher mortality and Hispanic patients had lower mortality than white patients.

Citation:

Rich NE, Hester C, Odewole M, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. [Published online ahead of print May 31, 2018]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2018.05.039.